Please login to the form below

Not currently logged in
Email:
Password:

Tysabri

This page shows the latest Tysabri news and features for those working in and with pharma, biotech and healthcare.

Novartis expands its generics franchise with natalizumab biosimilar

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access. Sandoz, Novartis’ generics unit, has agreed to license a biosimilar of Biogen’s Tysabri for multiple sclerosis from Polpharma Biologics. . ... The biosimilar franchise in Europe has grown in recent years,

Latest news

More from news
Approximately 4 fully matching, plus 94 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Elan / Perrigo. Acquisition. Tysabri royalty stream, R&D programmes/ EU HQ &operations.

  • Pharma deals during July 2013 Pharma deals during July 2013

    In addition to this is the very attractive tiered double digit royalty stream from Tysabri. ... Sales of Tysabri in 2012 were $1.6bn. Acquisitions - a route to bolstering a core business.

  • Pharma deals during May 2013 Pharma deals during May 2013

    The Elan/ Royalty Pharma saga began following Biogen Idec's decision in February to buy out the Tysabri rights from Elan for $3.25bn. ... Following the close of the Tysabri deal in early April, Elan went on a spending spree in May.

  • Pharma deals during February 2013 Pharma deals during February 2013

    Deal of the month. The largest agreed deal announced was Biogen Idec's acquisition of Elan's interest in Tysabri (natalizumab), the multiple sclerosis (MS) treatment, thereby terminating their previous collaboration ... Tysabri's sales amounted to $1.6bn

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    Prior to Momenta, Ottmer spent 16 years at Biogen in a variety of leadership roles including senior vice president, strategy and emerging businesses, head of Tysabri business, chief of staff to

  • Michael Fleming joins biosimilars firm Coherus Michael Fleming joins biosimilars firm Coherus

    Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise. ... Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Richard Kim led Tysabri programme at Biogen Idec. XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs. ... He joined XenoPort from Biogen Idec where he was joint programme team leader for

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • It's time to change the conversation

    connections. While promotional spend on their drug Tysabri at launch was focused on specialist detailing and medical events, the promotional mix has evolved with increased direct to consumer spend and direct

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....
marketing satnav
Mapping at launch: it’s time to update the satnav
How mapping familiar basics can provide a new GPS for market access strategy that drives brand success...

Infographics